|
1
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Anantharaman A and Frieddlaner TW:
Targeting the androgen receptor in metastatic castrate-resistant
prostate cancer: A review. Urol Oncol. 34:356–367. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Lonergan PE and Tindall DJ: Androgen
receptor signaling in prostate cancer development and progression.
J Carcinog. 10:202011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Chandrasekar T, Yang JC, Gao AC and Evans
CP: Mechanisms of resistance in castration-resistant prostate
cancer (CRPC). Transl Androl Urol. 4:365–380. 2015.PubMed/NCBI
|
|
5
|
Mitsiades N, Sung C, Schultz N, Danila DC,
He B, Eedunuri VK, Fleisher M, Sander C, Sawyers CL and Scher HI:
Distinct patterns of dysregulated expression of enzymes involved in
androgen synthesis and metabolism in metastatic prostate cancer
tumors. Cancer Res. 72:6142–6152. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Banerjee P, Banerjee S, Brown T and Zirkin
B: Androgen action in prostate function and disease. Am J Clin Exp
Urol. 6:62–77. 2018.PubMed/NCBI
|
|
7
|
Sun Y, Wang BE, Leong KG, Yue P, Li L,
Jhunjhunwala S, Chen D, Seo K, Modrusan Z, Gao WQ, et al: Androgen
deprivation causes epithelial-mesenchymal transition in the
prostate: Implications for androgen-deprivation therapy. Cancer
Res. 72:527–536. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Anose BM and Sanders MM: Androgen receptor
regulates transcription of the ZEB1 transcription factor. Int J
Endocrinol. 2011:9039182011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Orellana-Serradell O, Herrera D, Castellon
E and Contreras HR: The transcription factor ZEB1 promotes an
aggressive phenotype in prostate cancer cell lines. Asian J Androl.
20:294–299. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2-ΔΔCT method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Payne AH and Hales DB: Overview of
steroidogenic enzymes in the pathway from cholesterol to active
steroid hormones. Endocr Rev. 25:947–970. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Mostaghel EA: Steroid hormone synthetic
pathways in prostate cancer. Transl Androl Urol. 2:212–227.
2013.PubMed/NCBI
|
|
13
|
Chen M and Penning TM: 5β-Reduced steroids
and human Δ4-3-ketosteroid 5β-reductase (AKR1D1). Steroids.
83:17–26. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zeng CM, Chang LL, Ying MD, Cao J, He QJ,
Zhu H and Yang B: Aldo-keto reductase AKR1C1-AKR1C4: Functions,
regulation, and intervention for anti-cancer therapy. Front
Pharmacol. 8:1192017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Montgomery RB, Mostaghel EA, Vessella R,
Hess DL, Kalhorn TF, Higano CS, True LD and Nelson PS: Maintenance
of intratumoral androgens in metastatic prostate cancer: A
mechanism for castration-resistant tumor growth. Cancer Res.
68:4447–4454. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Rizner TL, Lin HK, Peehl DM, Steckelbroeck
S, Bauman DR and Penning TM: Human type 3 3alpha-hydroxysteroid
dehydrogenase (aldo-keto reductase 1 C2) and androgen metabolism in
prostate cells. Endocrinology. 144:2922–2932. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Basu S and Tindall DJ: Androgen action in
prostate cancer. Horm Cancer. 1:223–228. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Taylor BS, Schultz N, Hieronymus H,
Gopalan A, Xiao Y, Carver BS, Arora VK, Kaushik P, Cerami E, Reva
B, et al: Integrative genomic profiling of human prostate cancer.
Cancer Cell. 18:11–22. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhang A, Zhang J, Plymate S and Mostaghel
EA: Classical and non-classical roles for pre-receptor control of
DHT metabolism in prostate cancer progression. Horm Cancer.
7:104–113. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Huang KH, Chiou SH, Chow KC, Lin TY, Chang
HW, Chiang IP and Lee MC: Overexpression of aldo-keto reductase 1C2
is associated with disease progression in patients with prostatic
cancer. Histopathology. 57:384–394. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ji Q, Chang L, VanDenBerg D, Stanczyk FZ
and Stolz A: Selective reduction of AKR1C2 in prostate cancer and
its role in DHT metabolism. Prostate. 54:275–289. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kobayashi T, Inoue T, Kamba T and Ogawa O:
Experimental evidence of persistent androgen-receptor-dependency in
castration-resistant prostate cancer. Int J Mol Sci.
14:15615–15635. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Lubik A, Nouri M, Truong S, Ghaffari M,
Adomat HH, Corey E, Cox ME, Li N, Guns ES, Yenki P, et al:
Paracrine sonic hedgehog signaling contributes significantly to
acquired steroidogenesis in the prostate tumor microenvironment.
Int J Cancer. 140:358–369. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Audet-Walsh É, Yee T, Tam IS and Giguère
V: Inverse regulation of DHT synthesis enzymes 5α-reductase types 1
and 2 by the androgen receptor in prostate cancer. Endocrinology.
158:1015–1021. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Locke JA, Guns ES, Lubik AA, Adomat HH,
Hendy SC, Wood CA, Ettinger SL, Gleave ME and Nelson CC: Androgen
levels increase by intratumoral de novo steroidogenesis during
progression of castration-resistant prostate cancer. Cancer Res.
68:6407–6415. 2008. View Article : Google Scholar : PubMed/NCBI
|
